Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Psychological correlates of biological and non-biological explanations for stuttering.

Boyle MP.

Int J Speech Lang Pathol. 2019 Oct 1:1-9. doi: 10.1080/17549507.2019.1663931. [Epub ahead of print]

PMID:
31575286
2.

Disclosure of stuttering and quality of life in people who stutter.

Boyle MP, Milewski KM, Beita-Ell C.

J Fluency Disord. 2018 Dec;58:1-10. doi: 10.1016/j.jfludis.2018.10.003. Epub 2018 Oct 15.

PMID:
30352701
3.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

McColley SA, Konstan MW, Ramsey BW, Stuart Elborn J, Boyle MP, Wainwright CE, Waltz D, Vera-Llonch M, Marigowda G, Jiang JG, Rubin JL.

J Cyst Fibros. 2019 Jan;18(1):94-101. doi: 10.1016/j.jcf.2018.07.011. Epub 2018 Aug 23.

4.

Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

Dezube R, Jennings MT, Rykiel M, Diener-West M, Boyle MP, Chmiel JF, Dasenbrook EC.

J Cyst Fibros. 2019 May;18(3):357-363. doi: 10.1016/j.jcf.2018.07.005. Epub 2018 Aug 18.

PMID:
30131297
5.

Self-Esteem, Self-Efficacy, and Social Support as Predictors of Communicative Participation in Adults Who Stutter.

Boyle MP, Beita-Ell C, Milewski KM, Fearon AN.

J Speech Lang Hear Res. 2018 Aug 8;61(8):1893-1906. doi: 10.1044/2018_JSLHR-S-17-0443.

PMID:
29998290
6.

CFTR modulator theratyping: Current status, gaps and future directions.

Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL.

J Cyst Fibros. 2019 Jan;18(1):22-34. doi: 10.1016/j.jcf.2018.05.004. Epub 2018 Jun 20. Review.

7.

Enacted stigma and felt stigma experienced by adults who stutter.

Boyle MP.

J Commun Disord. 2018 May - Jun;73:50-61. doi: 10.1016/j.jcomdis.2018.03.004. Epub 2018 Mar 13.

PMID:
29574262
8.

Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis.

Hong G, Psoter KJ, Jennings MT, Merlo CA, Boyle MP, Hadjiliadis D, Kawut SM, Lechtzin N.

J Cyst Fibros. 2018 Sep;17(5):624-630. doi: 10.1016/j.jcf.2018.01.008. Epub 2018 Feb 12.

9.

Frequency of small-colony variants and antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.

Suwantarat N, Rubin M, Bryan L, Tekle T, Boyle MP, Carroll KC, Jennings MT.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):296-299. doi: 10.1016/j.diagmicrobio.2017.11.012. Epub 2017 Dec 2.

PMID:
29343421
10.

C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab.

Boyle MP, Moss AC, O'Toole AM, Vaughn B, Cheifetz AS.

J Dig Dis. 2017 Dec;18(12):678-683. doi: 10.1111/1751-2980.12560.

PMID:
29119722
11.

Self-stigma and its associations with stress, physical health, and health care satisfaction in adults who stutter.

Boyle MP, Fearon AN.

J Fluency Disord. 2018 Jun;56:112-121. doi: 10.1016/j.jfludis.2017.10.002. Epub 2017 Oct 24.

PMID:
29111141
12.

Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.

Polineni D, Dang H, Gallins PJ, Jones LC, Pace RG, Stonebraker JR, Commander LA, Krenicky JE, Zhou YH, Corvol H, Cutting GR, Drumm ML, Strug LJ, Boyle MP, Durie PR, Chmiel JF, Zou F, Wright FA, O'Neal WK, Knowles MR.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):79-93. doi: 10.1164/rccm.201701-0134OC.

13.

Personal Perceptions and Perceived Public Opinion About Stuttering in the United States: Implications for Anti-Stigma Campaigns.

Boyle MP.

Am J Speech Lang Pathol. 2017 Aug 15;26(3):921-938. doi: 10.1044/2017_AJSLP-16-0191.

PMID:
28785764
14.

Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results.

Lechtzin N, Mayer-Hamblett N, West NE, Allgood S, Wilhelm E, Khan U, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, Gibson RL, Orenstein D, Milla C, Clancy JP, Antony V, Goss CH; eICE Study Team.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1144-1151. doi: 10.1164/rccm.201610-2172OC.

15.

Risk factors for persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

Jennings MT, Dasenbrook EC, Lechtzin N, Boyle MP, Merlo CA.

J Cyst Fibros. 2017 Nov;16(6):681-686. doi: 10.1016/j.jcf.2017.04.010. Epub 2017 Apr 23.

16.

Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.

Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, Henning A, Ensign LM, Lee E, Adstamongkonkul P, Simons BW, Wang SS, Gong X, Yu T, Boyle MP, Suk JS, Hanes J.

Sci Adv. 2017 Apr 5;3(4):e1601556. doi: 10.1126/sciadv.1601556. eCollection 2017 Apr.

17.

Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.

Zeitlin PL, Diener-West M, Callahan KA, Lee S, Talbot CC Jr, Pollard B, Boyle MP, Lechtzin N.

Ann Am Thorac Soc. 2017 Feb;14(2):220-229. doi: 10.1513/AnnalsATS.201608-649OC.

18.

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.

Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP; VX09-809-102 Study Group.

Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC.

19.

A comparison of three strategies for reducing the public stigma associated with stuttering.

Boyle MP, Dioguardi L, Pate JE.

J Fluency Disord. 2016 Dec;50:44-58. doi: 10.1016/j.jfludis.2016.09.004. Epub 2016 Sep 30.

PMID:
27865229
20.

Microstructural alterations of sputum in cystic fibrosis lung disease.

Duncan GA, Jung J, Joseph A, Thaxton AL, West NE, Boyle MP, Hanes J, Suk JS.

JCI Insight. 2016 Nov 3;1(18):e88198. doi: 10.1172/jci.insight.88198.

21.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.

Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D, Wainwright CE; VX-809 TRAFFIC and TRANSPORT study groups.

Lancet Respir Med. 2016 Aug;4(8):617-626. doi: 10.1016/S2213-2600(16)30121-7. Epub 2016 Jun 10.

22.

The impact of causal attribution on stigmatizing attitudes toward a person who stutters.

Boyle MP.

J Commun Disord. 2016 Mar-Apr;60:14-26. doi: 10.1016/j.jcomdis.2016.02.002. Epub 2016 Feb 17.

PMID:
26928224
23.

The evidence for long-term benefits of restoration of CFTR function continues to grow.

Boyle MP.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):774-6. doi: 10.1164/rccm.201507-1348ED. No abstract available.

PMID:
26426780
24.

Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy.

Mastorakos P, da Silva AL, Chisholm J, Song E, Choi WK, Boyle MP, Morales MM, Hanes J, Suk JS.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8720-5. doi: 10.1073/pnas.1502281112. Epub 2015 Jun 29.

25.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

26.

Identifying correlates of self-stigma in adults who stutter: Further establishing the construct validity of the Self-Stigma of Stuttering Scale (4S).

Boyle MP.

J Fluency Disord. 2015 Mar;43:17-27. doi: 10.1016/j.jfludis.2014.12.002. Epub 2015 Jan 6.

PMID:
25614323
27.

Relationships between psychosocial factors and quality of life for adults who stutter.

Boyle MP.

Am J Speech Lang Pathol. 2015 Feb;24(1):1-12. doi: 10.1044/2014_AJSLP-14-0089.

PMID:
25410098
28.

Understanding perceptions of stuttering among school-based speech-language pathologists: an application of attribution theory.

Boyle MP.

J Commun Disord. 2014 Nov-Dec;52:143-55. doi: 10.1016/j.jcomdis.2014.06.003. Epub 2014 Jul 7.

PMID:
25042750
29.

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group.

Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24.

PMID:
24973281
30.
31.

Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors.

Schuster BS, Kim AJ, Kays JC, Kanzawa MM, Guggino WB, Boyle MP, Rowe SM, Muzyczka N, Suk JS, Hanes J.

Mol Ther. 2014 Aug;22(8):1484-1493. doi: 10.1038/mt.2014.89. Epub 2014 May 29.

32.

Patches of disorganization in the neocortex of children with autism.

Stoner R, Chow ML, Boyle MP, Sunkin SM, Mouton PR, Roy S, Wynshaw-Boris A, Colamarino SA, Lein ES, Courchesne E.

N Engl J Med. 2014 Mar 27;370(13):1209-1219. doi: 10.1056/NEJMoa1307491.

33.

Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project.

Boyle MP, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS.

BMJ Qual Saf. 2014 Apr;23 Suppl 1:i15-i22. doi: 10.1136/bmjqs-2013-002369. Review.

PMID:
24608546
34.

Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.

Suk JS, Kim AJ, Trehan K, Schneider CS, Cebotaru L, Woodward OM, Boylan NJ, Boyle MP, Lai SK, Guggino WB, Hanes J.

J Control Release. 2014 Mar 28;178:8-17. doi: 10.1016/j.jconrel.2014.01.007. Epub 2014 Jan 14.

35.

Update on key emerging challenges in cystic fibrosis.

Jennings MT, Riekert KA, Boyle MP.

Med Princ Pract. 2014;23(5):393-402. doi: 10.1159/000357646. Epub 2014 Jan 10. Review.

36.

A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.

Boyle MP, De Boeck K.

Lancet Respir Med. 2013 Apr;1(2):158-63. doi: 10.1016/S2213-2600(12)70057-7. Epub 2013 Jan 30. Review. Erratum in: Lancet Respir Med. 2013 Apr;1(2):101.

PMID:
24429096
37.

Psychological characteristics and perceptions of stuttering of adults who stutter with and without support group experience.

Boyle MP.

J Fluency Disord. 2013 Dec;38(4):368-81. doi: 10.1016/j.jfludis.2013.09.001. Epub 2013 Oct 1.

PMID:
24331244
38.

Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.

Lechtzin N, West N, Allgood S, Wilhelm E, Khan U, Mayer-Hamblett N, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, Goss CH.

Contemp Clin Trials. 2013 Nov;36(2):460-9. doi: 10.1016/j.cct.2013.09.004. Epub 2013 Sep 19.

39.

Assessment of stigma associated with stuttering: development and evaluation of the self-stigma of stuttering scale (4S).

Boyle MP.

J Speech Lang Hear Res. 2013 Oct;56(5):1517-29. doi: 10.1044/1092-4388(2013/12-0280). Epub 2013 Jul 9.

PMID:
23838992
40.

Familiarity breeds support: speech-language pathologists' perceptions of bullying of students with autism spectrum disorders.

Blood GW, Blood IM, Coniglio AD, Finke EH, Boyle MP.

J Commun Disord. 2013 Mar-Apr;46(2):169-80. doi: 10.1016/j.jcomdis.2013.01.002. Epub 2013 Jan 31.

PMID:
23497960
41.

Temperature sensitivity of capillary-driven flow: application to age monitoring devices.

Thomas JA, Boyle MP, Hunter LW, Tiffany JE.

J Colloid Interface Sci. 2012 Apr 15;372(1):176-82. doi: 10.1016/j.jcis.2012.01.008. Epub 2012 Jan 20.

PMID:
22300654
42.

Self-reported experience of bullying of students who stutter: relations with life satisfaction, life orientation, and self-esteem.

Blood GW, Blood IM, Tramontana GM, Sylvia AJ, Boyle MP, Motzko GR.

Percept Mot Skills. 2011 Oct;113(2):353-64.

PMID:
22185050
43.

Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation.

Boylan NJ, Suk JS, Lai SK, Jelinek R, Boyle MP, Cooper MJ, Hanes J.

J Control Release. 2012 Jan 10;157(1):72-9. doi: 10.1016/j.jconrel.2011.08.031. Epub 2011 Aug 31.

44.

N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.

Suk JS, Boylan NJ, Trehan K, Tang BC, Schneider CS, Lin JM, Boyle MP, Zeitlin PL, Lai SK, Cooper MJ, Hanes J.

Mol Ther. 2011 Nov;19(11):1981-9. doi: 10.1038/mt.2011.160. Epub 2011 Aug 9.

45.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, OrdoƱez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.

46.

Mindfulness training in stuttering therapy: a tutorial for speech-language pathologists.

Boyle MP.

J Fluency Disord. 2011 Jun;36(2):122-9. doi: 10.1016/j.jfludis.2011.04.005. Epub 2011 Apr 23.

PMID:
21664530
47.

Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients.

Hida K, Lai SK, Suk JS, Won SY, Boyle MP, Hanes J.

PLoS One. 2011;6(5):e19919. doi: 10.1371/journal.pone.0019919. Epub 2011 May 27.

48.

Cell-type-specific consequences of Reelin deficiency in the mouse neocortex, hippocampus, and amygdala.

Boyle MP, Bernard A, Thompson CL, Ng L, Boe A, Mortrud M, Hawrylycz MJ, Jones AR, Hevner RF, Lein ES.

J Comp Neurol. 2011 Aug 1;519(11):2061-89. doi: 10.1002/cne.22655.

PMID:
21491433
49.

Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA.

J Cyst Fibros. 2011 Jul;10(4):258-64. doi: 10.1016/j.jcf.2011.03.005. Epub 2011 Mar 31.

50.

Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosis.

West NE, Lechtzin N, Merlo CA, Turowski JB, Davis ME, Ramsay MZ, Watts SL, Stenner SP, Boyle MP.

Chest. 2011 Aug;140(2):469-474. doi: 10.1378/chest.10-2114. Epub 2011 Mar 10.

PMID:
21393390

Supplemental Content

Loading ...
Support Center